会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Xanthene derivatives, their production and use
    • 呫吨衍生物,其生产和使用
    • US06221637B1
    • 2001-04-24
    • US08812946
    • 1997-03-04
    • Tsuneaki HidaMasahiko HattoriTsutomu KurokawaAtsushi Nakanishi
    • Tsuneaki HidaMasahiko HattoriTsutomu KurokawaAtsushi Nakanishi
    • C12P1702
    • C07D405/12C07D311/82C07D311/86C07D407/04C07D409/04C07K14/70521
    • Xanthene compounds represented by the formula: wherein R1 is a carboxyl group which may be esterified or amidated; R2 is a hydrogen atom, a hydroxyl group, or a hydrocarbon group which may be substituted; R3 and R4 are the same or different and are a hydroxyl group which may be substituted; R5 and R6 are a hydrogen atom or a halogen atom; R7 is a hydrogen atom, a nitro group, a halogen atom, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted, or an acyl group which may be substituted; n is an integer of 0 to 2; and Y is an oxygen atom or two hydrogen atoms; and when n is 0, R2 may be a group represented by the formula: wherein the symbols have the same meanings as defined above, or a salt thereof inhibit a binding of B7-1 to CD28, prevent the B7-1-dependent activation of T cells and inhibit IL-2 production from T cells, thus being used as an immunomodulator such as a graft rejection inhibitor or a pharmaceutical composition for therapeutic treatment of allergy, rheumatoid arthritis, autoimmune disease, nephritis, diabetes mellitus and so on.
    • 由下式表示的呫吨化合物:其中R1是可被酯化或酰胺化的羧基; R2是氢原子,羟基或可被取代的烃基; R3和R4相同或不同,为可被取代的羟基; R5和R6是氢原子或卤素原子; R7是氢原子,硝基,卤素原子,可被取代的烃基,可被取代的杂环基或可被取代的酰基; n为0〜2的整数, Y是氧原子或两个氢原子; 当n为0时,R2可以是由下式表示的基团:其中符号具有与上述相同的含义,或其盐抑制B7-1与CD28的结合,防止B7-1依赖性的活化 T细胞,抑制T细胞的IL-2产生,作为免疫调节剂,例如移植排斥抑制剂或用于治疗过敏,类风湿性关节炎,自身免疫性疾病,肾炎,糖尿病等的药物组合物。
    • 4. 发明授权
    • Antibodies to peptides having NGF-like activity, said antibodies having
no substantial cross-reactivity with NGF, and use thereof
    • 具有NGF样活性的肽的抗体,所述抗体与NGF无相当的交叉反应性及其用途
    • US5656435A
    • 1997-08-12
    • US350214
    • 1994-12-06
    • Kazuo NakahamaTsunehiko FukudaTsutomu KurokawaKen-ichi Kuroshima
    • Kazuo NakahamaTsunehiko FukudaTsutomu KurokawaKen-ichi Kuroshima
    • C07K14/48C07K16/22C12P21/08G01N33/53C12N5/20
    • C07K14/48C07K16/22
    • Disclosed are (A) an antibody to a peptide including at least 8 successive amino acids of an amino acid sequence represented by formulaTyrAlaGluHisLysSerHisArgGlyGluTyrSerValCys AspSerGluSerLeuTrpValThrAspLysSerSerAlaIle AspIleArgGlyHisGlnValThrValLeuGlyGluIleLys ThrGlyAsnSerProValLysGlnTyrPheTyrGluThrArg CysLysGluAlaArgProValLysAsnGlyCysArgGlyIle AspAspLysHisTrpAsnSerGlnCysLysThrSerGlnThr TyrValArgAlaLeuThrSerGluAsnAsnLysLeuValGly TrpArgTrpIleArgIleAspThrSerCysValCysAlaLeu SerArgLysIleGlyArg[1],wherein said antibody has no substantial cross-reactivity with human NGF,(B) a method for producing the antibody, (C) a cloned hybridoma which produces the antibody, (D) a method for producing the cloned hybridoma, (E) a partial peptide of a polypeptide (I) including an amino acid sequence represented by formula (1), (F) a conjugate of a peptide including at least 8 successive amino acids of formula (1) with a carrier protein, (G) a method for purifying the polypeptide (I) and (H) a method for detecting and assaying the polypeptide (I).
    • 所公开的是(A)的抗体的肽,包括由formulaTyrAlaGluHisLysSerHisArgGlyGluTyrSerValCys AspSerGluSerLeuTrpValThrAspLysSerSerAlaIle AspIleArgGlyHisGlnValThrValLeuGlyGluIleLys ThrGlyAsnSerProValLysGlnTyrPheTyrGluThrArg CysLysGluAlaArgProValLysAsnGlyCysArgGlyIle AspAspLysHisTrpAsnSerGlnCysLysThrSerGlnThr TyrValArgAlaLeuThrSerGluAsnAsnLysLeuValGly TrpArgTrpIleArgIleAspThrSerCysValCysAlaLeu SerArgLysIleGlyArg [1]表示的氨基酸序列的至少8种连续氨基酸,其中所述抗体不具有实质性的交叉反应性的人NGF, (B)产生抗体的方法,(C)产生抗体的克隆杂交瘤,(D)克隆的杂交瘤的制备方法,(E)多肽(I)的部分肽,其包含氨基酸序列 通式(1),(F)包含式(1)的至少8个连续氨基酸的肽与载体蛋白的缀合物,(G)纯化多肽(I)的方法和(H) 检测和测定多肽(I)。